Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
The latest update is out from Serina Therapeutics ( (SER) ).
Serina Therapeutics has announced the development of its lead program, SER-252, which is set to enter clinical trials in 2025 as a novel treatment for advanced Parkinson’s disease. The POZ Platform® developed by Serina aims to optimize drug delivery and reduce immunogenicity, positioning the company as a competitive player in the biotechnology industry. The platform offers significant improvements in drug delivery, including continuous release and safe metabolism, which could greatly impact treatment options for Parkinson’s patients and potentially capture a significant market share.
More about Serina Therapeutics
Serina Therapeutics is a biotechnology company focused on developing therapeutic polymer platforms for small molecules, RNA, and antibody-drug conjugates (ADCs). The company has a proven record in drug development and commercialization, with its founders having pioneered PEGylation at Shearwater Polymers. Serina is involved in partnerships with major companies such as Pfizer and has key investors that have led significant funding rounds.
YTD Price Performance: 1.51%
Average Trading Volume: 25,415
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $46.04M
Learn more about SER stock on TipRanks’ Stock Analysis page.
